NCT06299709View on ClinicalTrials.gov

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

May 23, 2024

Study Completion Date

May 23, 2024

Conditions

Cystic Fibrosis

Interventions

DRUG

VNZ/TEZ/D-IVA

FDC tablet for oral administration.

DRUG

VNZ/TEZ/D-IVA

FDC granules for oral administration.

Trial Locations (1)

85283

Celerion, Inc., Tempe

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06299709 - A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) | Biotech Hunter | Biotech Hunter